Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal
Disease Category: Leukemia
Location: United States, OH
A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia
What is the purpose of this study?
There are two parts of this study. This first part is a Phase 1
study of a drug called epratuzumab, used alone and in combination
with chemotherapy drugs used to treat acute lymphoblastic leukemia
that has come beck (recurred). Epratuzumab is considered
experimental because it has not been approved by the Food and Drug
Administration (FDA). This study is being done to determine if
epratuzumab that can be given safely, both alone and with other
chemotherapy drugs. A safe medication is one that does not cause
unacceptable side effects. After the feasibility part of this study
has been completed, and found that epratuzumab could be given to
children with acute lymphoblastic leukemia, another type of study,
called a Phase 2 study will be done to find out if epratuzumab,
when given along with chemotherapy, is a helpful and an effective
therapy for treating children with acute lymphoblastic leukemia
that has come back after treatment.
The goals of this study are:
Who will be included in this study?
- To find out if epratuzumab, given both alone and with
chemotherapy drugs, can be given without causing severe side
- To learn what kind of side effects epratuzumab, given with
chemotherapy drugs, can cause;
- To learn more about the pharmacology (how the body handles the
drug) of epratuzumab;
- To determine whether epratuzumab with chemotherapy is a
beneficial treatment for this type of cancer;
- To learn more about this type of leukemia.
Patients who are 21 years old and younger who have experienced a
relapse of acute lymphoblastic leukemia may be eligible to
participate in this clinical trial.
What is involved?
Before beginning the study...
Participants will need to have the following exams, tests, or
procedures to find out if they can be in the study. These exams,
tests, or procedures are part of regular cancer care and may be
done even if they do not join the study. If participants have had
some of these tests recently, they may not need to be repeated.
This will be up to the study doctor.
During the study...
- Medical history
- Physical exam
- Vital signs such as blood pressure, pulse, and temperature
- Blood tests
- Urine tests
- Pregnancy test for women who could have children
- Lumbar puncture to test the fluid in the spinal cord
- Bone marrow test to check the leukemia
If the exams, tests, and procedures show that participants can
be in this study, and they choose to take part in the study,
several tests will need to be done to see how the leukemia is
responding to this treatment, and to monitor for any side effects.
These tests are a part of standard care for leukemia and may be
done even if participants do not join this study:
- Physical exam; at least weekly
- Vital signs, such as blood pressure, pulse, temperature;
- Blood tests; at least weekly
- Urine tests
- Bone marrow tests to find out if the disease is getting
- Chest x-ray
- Echocardiogram to check heart function
- Lumbar puncture with every dose of intrathecal
Part A of the study is approximately 17 weeks, and Part B of the
study is approximately 15 weeks.
We would like to continue to find out about the health of the
participant for about 5 years after the study closes to new
patients. If they do not visit our clinic at least once a year
after treatment ends, we would like to do this by calling on the
telephone once a year ( for 5 years) to check how the participant
is doing. Keeping in touch and checking on how the participant’s
health every year for a while after the study closes helps us
understand the long-term effects of the study.
What are the benefits?
There may be no direct benefit to participants for taking part in
this research study. It is unlikely that they will experience
significant benefit or cure from this drug, epratuzumab. Because
there is not much information about the effects of epratuzumab in
children, we do not know if participants will benefit from taking
part in this study. While doctors hope epratuzumab with
chemotherapy will be more useful against leukemia compared to the
usual treatment, there is no proof of this yet. The disease may
continue to become worse despite taking this drug. The potential
benefit is that epratuzumab may stop the relapsed acute
lymphoblastic leukemia from growing or go into partial remission
for a period of time. It may lessen the symptoms, such as pain,
that are caused by the cancer. The knowledge gained from this study
may benefit others in the future.
Will I get all the facts about the study?
Parents interested in having their child participate will be
scheduled with a physician who will thoroughly explain all of the
details of the study. The physician will review the consent form
with the parent/patient and will be sure that all questions are
answered. The consent form goes over all of the procedures, the
risks, the benefits, the compensation, who to contact with
questions or concerns and more. Study procedures will not begin
until a parent/guardian has signed this form and, if of age, the
child has given at minimum his/her verbal agreement.
What are the risks?
A detailed list of side effects will be provided to those patients
interested in knowing more about the study.
Who should I contact for more information?
Rebecca Turner, CCRP, RN, BSN
Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Division of Hematology/Oncology, MLC 11013
3333 Burnet Ave.
Cincinnati, OH 45229-3039
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these